Drug for reducing antibiotic resistance and killing bacteria
Technology
Betatide is a novel synthetic cell-penetrating peptide that attacks bacteria in a fundamentally new way. It reduces antibiotic resistance development and act as an antibiotic.
Market
Treatment of skin, lung, prosthetic joint infections and other infections caused by drug-resistant bacteria.
Uniqueness
- New MoA and target; targets the bacterial cell envelope, the translation and replication machinery.
- Broad single agent effects towards priority pathogens (all ESKAPE pathogens).
- Potentiate effect of other antibiotics and reduces the development of resistance.
- Successful studies in several animal models of infection.
- No nephrotoxicity or other major toxic effects.
Status
- 1st generation Betatide patent granted in several countries. Several publications. 2nd generation Betatide patent to be submitted early 2026. Ongoing studies in animal model of bacterial lung infection.
- Searching for commercial partners.
